

Shaomin Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2131917/publications.pdf>

Version: 2024-02-01

33
papers

6,631
citations

257450

24
h-index

414414

32
g-index

37
all docs

37
docs citations

37
times ranked

9231
citing authors

#	ARTICLE	IF	CITATIONS
1	Disruption of the IL-33-ST2-AKT signaling axis impairs neurodevelopment by inhibiting microglial metabolic adaptation and phagocytic function. <i>Immunity</i> , 2022, 55, 159-173.e9.	14.3	52
2	Bioactive human Alzheimer brain soluble A β : pathophysiology and therapeutic opportunities. <i>Molecular Psychiatry</i> , 2022, 27, 3182-3191.	7.9	14
3	A β oligomers from human brain impair mossy fiber LTP in CA3 of hippocampus, but activating cAMP-PKA and cGMP-PKG prevents this. <i>Neurobiology of Disease</i> , 2022, 172, 105816.	4.4	8
4	Environmental enrichment prevents A β oligomer-induced synaptic dysfunction through mirna-132 and hdac3 signaling pathways. <i>Neurobiology of Disease</i> , 2020, 134, 104617.	4.4	36
5	A mechanistic hypothesis for the impairment of synaptic plasticity by soluble A β oligomers from Alzheimer's brain. <i>Journal of Neurochemistry</i> , 2020, 154, 583-597.	3.9	158
6	Verubecestat for Prodromal Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2019, 381, 388-389.	27.0	10
7	Iron promotes β -synuclein aggregation and transmission by inhibiting TFE β -mediated autophagosome-lysosome fusion. <i>Journal of Neurochemistry</i> , 2018, 145, 34-50.	3.9	40
8	Astrocytic glutamatergic transporters are involved in A β -induced synaptic dysfunction. <i>Brain Research</i> , 2018, 1678, 129-137.	2.2	37
9	Decoding the synaptic dysfunction of bioactive human AD brain soluble A β to inspire novel therapeutic avenues for Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2018, 6, 121.	5.2	46
10	MicroRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways. <i>Acta Neuropathologica</i> , 2018, 136, 537-555.	7.7	120
11	Soluble A β Oligomers Impair Dipolar Heterodendritic Plasticity by Activation of mGluR in the Hippocampal CA1 Region. <i>iScience</i> , 2018, 6, 138-150.	4.1	14
12	Association of IGF1 gene polymorphism with Parkinson's disease in a Han Chinese population. <i>Journal of Gene Medicine</i> , 2017, 19, e2949.	2.8	7
13	Rapamycin upregulates glutamate transporter and IL-6 expression in astrocytes in a mouse model of Parkinson's disease. <i>Cell Death and Disease</i> , 2017, 8, e2611-e2611.	6.3	40
14	Human Brain-Derived A β Oligomers Bind to Synapses and Disrupt Synaptic Activity in a Manner That Requires APP. <i>Journal of Neuroscience</i> , 2017, 37, 11947-11966.	3.6	108
15	Large Soluble Oligomers of Amyloid β -Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate. <i>Journal of Neuroscience</i> , 2017, 37, 152-163.	3.6	262
16	MicroRNA expressing profiles in A53T mutant alpha-synuclein transgenic mice and Parkinsonian. <i>Oncotarget</i> , 2017, 8, 15-28.	1.8	52
17	Enhancing Beta-Catenin Activity via GSK3beta Inhibition Protects PC12 Cells against Rotenone Toxicity through Nurr1 Induction. <i>PLoS ONE</i> , 2016, 11, e0152931.	2.5	26
18	Association of DYRK1A polymorphisms with sporadic Parkinson's disease in Chinese Han population. <i>Neuroscience Letters</i> , 2016, 632, 39-43.	2.1	17

#	ARTICLE	IF	CITATIONS
19	The biomarkers of immune dysregulation and inflammation response in Parkinson disease. <i>Translational Neurodegeneration</i> , 2016, 5, 16.	8.0	53
20	Soluble A β oligomers impair hippocampal LTP by disrupting glutamatergic/GABAergic balance. <i>Neurobiology of Disease</i> , 2016, 85, 111-121.	4.4	120
21	Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline. <i>Journal of Neuroscience</i> , 2015, 35, 13029-13042.	3.6	286
22	Secreted Amyloid β -Proteins in a Cell Culture Model Include N-Terminally Extended Peptides That Impair Synaptic Plasticity. <i>Biochemistry</i> , 2014, 53, 3908-3921.	2.5	85
23	Environmental Novelty Activates β 2-Adrenergic Signaling to Prevent the Impairment of Hippocampal LTP by A β Oligomers. <i>Neuron</i> , 2013, 77, 929-941.	8.1	152
24	Soluble A β Oligomers Inhibit Long-Term Potentiation through a Mechanism Involving Excessive Activation of Extrasynaptic NR2B-Containing NMDA Receptors. <i>Journal of Neuroscience</i> , 2011, 31, 6627-6638.	3.6	530
25	How do soluble oligomers of amyloid β -protein impair hippocampal synaptic plasticity?. <i>Frontiers in Cellular Neuroscience</i> , 2010, 4, 5.	3.7	27
26	Soluble Oligomers of Amyloid β Protein Facilitate Hippocampal Long-Term Depression by Disrupting Neuronal Glutamate Uptake. <i>Neuron</i> , 2009, 62, 788-801.	8.1	818
27	Amyloid- β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. <i>Nature Medicine</i> , 2008, 14, 837-842.	30.7	3,225
28	The effect of atropine administered in the medial septum or hippocampus on high- and low-frequency theta rhythms in the hippocampus of urethane anesthetized rats. <i>Synapse</i> , 2007, 61, 412-419.	1.2	37
29	A brief, but repeated, swimming protocol is sufficient to overcome amyloid β -protein inhibition of hippocampal long-term potentiation. <i>European Journal of Neuroscience</i> , 2007, 26, 1289-1298.	2.6	8
30	The Environment versus Genetics in Controlling the Contribution of MAP Kinases to Synaptic Plasticity. <i>Current Biology</i> , 2006, 16, 2303-2313.	3.9	50
31	Distinct Roles for Ras-Guanine Nucleotide-Releasing Factor 1 (Ras-GRF1) and Ras-GRF2 in the Induction of Long-Term Potentiation and Long-Term Depression. <i>Journal of Neuroscience</i> , 2006, 26, 1721-1729.	3.6	172
32	Atropine acts in both medial septum and hippocampus to suppress theta rhythm in urethane anesthetized rats. <i>FASEB Journal</i> , 2006, 20, LB22.	0.5	0
33	GABAergic Control of the Ascending Input From the Median Raphe Nucleus to the Limbic System. <i>Journal of Neurophysiology</i> , 2005, 94, 2561-2574.	1.8	21